HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 56141

HXB2 Location  Gag(151-159)   Gag Epitope Map
View variants at this location
Epitope TLNAWVKVV   Epitope Alignment
Variants
TLNAWVKVi   diminished response
TLNAWVKaV   susceptible form
TLNAWVKai   susceptible form
Epitope Name TV9
Species (MHC/HLA human, transgenic mouse(A2)

Variant Details

Showing all: 3 variant(s).


Variant ID.  80
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKVi
Mutations V/I
Epitope Location V9I
HXB2 Location V159I
Mutation Type DR: diminished response
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.


Variant ID.  81
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKaV
Mutations V/A
Epitope Location V8A
HXB2 Location V158A
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.


Variant ID.  82
Epitope Seq.  TLNAWVKVV
Variant Seq.  TLNAWVKai
Mutations V/A V/I
Epitope Location V8A V9I
HXB2 Location V158A V159I
Mutation Type SF: susceptible form
Method CD8 T-cell Elispot - IFNy, Chromium-release assay
Note To identify immunogenically optimized epitopes for use in vaccines, mutants of TV9 were tested in transgenic mice. Natural TV9 mutants tested in transgenic HLA-A*02 mice showed the following responses - the common mutant V9I, TLNAWVKVi was less immunogenic and had low cross-reactivity. TLNAWVKaV (most cross-reactive) and TLNAWVKai were highly immunogenic and cross-reactive to the consensus.

References

Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health